Mesoblast shares savaged on poor trial results for COVID treatment

Mesoblast chief executive Silviu Itescu. The company was hoping to show its flagship product, remestemcel-L, would help patients with moderate to severe respiratory distress because of coronavirus.CREDIT:CREDIT: ARSINEH HOUSPIAN https://www.smh.com.au/business/companies/mesoblast-shares-savaged-on-poor-covid-trial-results-20201218-p56onp.html

Rate this:

Read Article →